Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
85 hedge funds and large institutions have $58.9M invested in Paratek Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 14 closing their positions.
20% more call options, than puts
Call options by funds: $580K | Put options by funds: $482K
9% less funds holding
Funds holding: 93 → 85 (-8)
16% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 32
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
36% less capital invested
Capital invested by funds: $92.2M → $58.9M (-$33.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$4.25M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.25M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.11M |
| 4 |
BC
Bruce & Co
Chicago,
Illinois
|
+$738K |
| 5 |
GAI
General American Investors
New York
|
+$586K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$9.14M |
| 2 |
JP Morgan Chase
New York
|
-$5.61M |
| 3 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$2.97M |
| 4 |
APCM
Arbiter Partners Capital Management
New York
|
-$2.42M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.81M |
PRTK Hedge Fund Activity: Q1 2020 in Review
85 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2020, worth a combined $58.9M — down 36% from $92.2M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PRTK and 9 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 27 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $4.25M. The largest seller was Armistice Capital, exiting entirely with an estimated $9.14M sold.
- 85 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2020, down from 93 in Q4 2019.
- Funds reported $58.9M of Paratek Pharmaceuticals, Inc. stock for Q1 2020, down 36% quarter-over-quarter.
- 9 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2020 and 14 closed out, a net change of -5 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2020 was Rock Springs Capital Management, an estimated $4.25M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2020 was Armistice Capital, an estimated $9.14M sold.
Based on aggregated 13F filings for Q1 2020.